A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
lebrikizumab
montelukast [Singulair]
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Inclusion Criteria:
- Age 18-75 years old at study start
- Asthma diagnosis for >/= 12 months prior to study start
- Bronchodilator response at screening
- Pre-bronchodilator FEV1 of 60% - 85% predicted at both screening visits 2 and 3
- No other clinically significant lung disease as confirmed by chest X-ray or computed tomography (CT) scan
- Stable and symptomatic asthma during the screening period
- Use of effective contraception, as defined by the protocol, until 24 weeks after the last dose
Exclusion Criteria:
- Maintenance of corticosteroid therapy, defined as daily or alternate-day oral corticosteroid maintenance therapy within 3 months prior to study start
- Treatment with systemic or inhaled corticosteroids within 4 weeks prior to study start or during the screening period for any reason, including an acute exacerbation event
- Treatment with a leukotriene receptor antagonist (LTRA), long-acting beta-agonist (LABA) long-acting muscarinic antagonist (LAMA), zileuton, roflumilast, or theophylline within 2 weeks prior to study start
- Documented prior treatment failure with Montelukast
- Treatment with intra-articular corticosteroids within 4 weeks prior to study start or during the screening period or anticipated need for intra articular corticosteroids during the course of the study
- Any infection requiring hospital, IV or IM antibiotic treatment or any respiratory infection within 4 weeks of study start. Any infection requiring oral antibiotic treatment within 2 weeks of study start, or any parasitic infection within 6 months of study start
- Clinically significant abnormality found during screening or clinically significant medical disease that is uncontrolled despite treatment that is likely, in the opinion of the investigator, to impact the patient's ability to participate in the study, or impact the study assessments
- History of interstitial lung disease, chronic obstructive pulmonary disease (COPD), or other clinically significant lung disease other than asthma
- History of alcohol or drug abuse that would impair or risk the patient's full participation in the study, in the opinion of the investigator
- Current or history of smoking (> 10 pack-years), or unwillingness to abstain from smoking for the duration of the study
- Past and/or current use of any anti-IL-13 or anti- IL4/IL-13 therapy, including lebrikizumab
- Use of a licensed or investigational monoclonal antibody other than anti IL-13 or anti-IL-4/IL-13, including, but not limited to, omalizumab, anti-IL-5, or anti IL-17, within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
- Use of a systemic immunomodulatory or immunosuppressive therapy within 3 months or 5 drug half-lives prior to study start or during screening
- Use of other investigational therapy within 4 weeks or 5 drug half-lives prior to study start (whichever is longer) or during screening
- Initiation of or change in allergen immunotherapy within 3 months prior to study start or during screening
- Receipt of a live attenuated vaccine within 4 weeks prior to study start of during screening
- Pregnancy or breast feeding
- Body mass index > 38 kg/m2
- Body weight < 40 kg
- History of bronchial thermoplasty
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Active Comparator
Experimental
Arm Label
Placebo
Singulair (montelukast)
lebrikizumab
Arm Description
Outcomes
Primary Outcome Measures
Absolute change in pre-bronchodilator forced expiratory volume in 1 second (FEV1)
Secondary Outcome Measures
Relative change in morning pre-bronchodilator peak expiratory flow (PEF)
Time to treatment failure
Change in asthma rescue medication use
Incidence of adverse events
Pharmacodynamics: Relative change in fractional exhaled nitric oxide (FeNO)
Pharmacodynamics: Change in blood eosinophil count
Pharmacokinetics: Maximum serum lebrikizumab concentration after the first dose (Cmax)
Change in patient-reported outcome, as measured by the Standardized Asthma Quality of Life Questionnaire (AQLQ(S))
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02104674
Brief Title
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
Official Title
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE ASTHMA
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
May 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
4. Oversight
5. Study Description
Brief Summary
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will assess the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist (SABA) therapy alone. Patients will be randomized in a 1:1:1 ratio to receive either blinded lebrikizumab or placebo treatment by subcutaneous (SC) injection (every 4 weeks for a total of 3 doses) or open-label treatment with Singulair (Montelukast; 10 mg daily). Time on study treatment will last 12 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
313 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
Singulair (montelukast)
Arm Type
Active Comparator
Arm Title
lebrikizumab
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
lebrikizumab
Intervention Description
Given SC on Days 1, 29, and 57
Intervention Type
Drug
Intervention Name(s)
montelukast [Singulair]
Intervention Description
10 mg given orally once daily for 12 weeks
Intervention Type
Other
Intervention Name(s)
placebo
Intervention Description
SC injection given on Days 1, 29, and 57
Primary Outcome Measure Information:
Title
Absolute change in pre-bronchodilator forced expiratory volume in 1 second (FEV1)
Time Frame
From Baseline to Week 12
Secondary Outcome Measure Information:
Title
Relative change in morning pre-bronchodilator peak expiratory flow (PEF)
Time Frame
From Baseline to Week 12
Title
Time to treatment failure
Time Frame
From Baseline to Week 12
Title
Change in asthma rescue medication use
Time Frame
From Baseline to Week 12
Title
Incidence of adverse events
Time Frame
Approximately 20 weeks
Title
Pharmacodynamics: Relative change in fractional exhaled nitric oxide (FeNO)
Time Frame
From Baseline to Week 12
Title
Pharmacodynamics: Change in blood eosinophil count
Time Frame
From Baseline to Week 12
Title
Pharmacokinetics: Maximum serum lebrikizumab concentration after the first dose (Cmax)
Time Frame
Week 1
Title
Change in patient-reported outcome, as measured by the Standardized Asthma Quality of Life Questionnaire (AQLQ(S))
Time Frame
From Baseline to Week 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18-75 years old at study start
Asthma diagnosis for >/= 12 months prior to study start
Bronchodilator response at screening
Pre-bronchodilator FEV1 of 60% - 85% predicted at both screening visits 2 and 3
No other clinically significant lung disease as confirmed by chest X-ray or computed tomography (CT) scan
Stable and symptomatic asthma during the screening period
Use of effective contraception, as defined by the protocol, until 24 weeks after the last dose
Exclusion Criteria:
Maintenance of corticosteroid therapy, defined as daily or alternate-day oral corticosteroid maintenance therapy within 3 months prior to study start
Treatment with systemic or inhaled corticosteroids within 4 weeks prior to study start or during the screening period for any reason, including an acute exacerbation event
Treatment with a leukotriene receptor antagonist (LTRA), long-acting beta-agonist (LABA) long-acting muscarinic antagonist (LAMA), zileuton, roflumilast, or theophylline within 2 weeks prior to study start
Documented prior treatment failure with Montelukast
Treatment with intra-articular corticosteroids within 4 weeks prior to study start or during the screening period or anticipated need for intra articular corticosteroids during the course of the study
Any infection requiring hospital, IV or IM antibiotic treatment or any respiratory infection within 4 weeks of study start. Any infection requiring oral antibiotic treatment within 2 weeks of study start, or any parasitic infection within 6 months of study start
Clinically significant abnormality found during screening or clinically significant medical disease that is uncontrolled despite treatment that is likely, in the opinion of the investigator, to impact the patient's ability to participate in the study, or impact the study assessments
History of interstitial lung disease, chronic obstructive pulmonary disease (COPD), or other clinically significant lung disease other than asthma
History of alcohol or drug abuse that would impair or risk the patient's full participation in the study, in the opinion of the investigator
Current or history of smoking (> 10 pack-years), or unwillingness to abstain from smoking for the duration of the study
Past and/or current use of any anti-IL-13 or anti- IL4/IL-13 therapy, including lebrikizumab
Use of a licensed or investigational monoclonal antibody other than anti IL-13 or anti-IL-4/IL-13, including, but not limited to, omalizumab, anti-IL-5, or anti IL-17, within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
Use of a systemic immunomodulatory or immunosuppressive therapy within 3 months or 5 drug half-lives prior to study start or during screening
Use of other investigational therapy within 4 weeks or 5 drug half-lives prior to study start (whichever is longer) or during screening
Initiation of or change in allergen immunotherapy within 3 months prior to study start or during screening
Receipt of a live attenuated vaccine within 4 weeks prior to study start of during screening
Pregnancy or breast feeding
Body mass index > 38 kg/m2
Body weight < 40 kg
History of bronchial thermoplasty
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
City
Flagstaff
State/Province
Arizona
ZIP/Postal Code
86001
Country
United States
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85251
Country
United States
City
Alhambra
State/Province
California
ZIP/Postal Code
91801
Country
United States
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
City
Napa
State/Province
California
ZIP/Postal Code
94558
Country
United States
City
Rancho Mirage
State/Province
California
ZIP/Postal Code
92270
Country
United States
City
Redwood City
State/Province
California
ZIP/Postal Code
94063
Country
United States
City
Stockton
State/Province
California
ZIP/Postal Code
95207
Country
United States
City
Upland
State/Province
California
ZIP/Postal Code
91786
Country
United States
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80907
Country
United States
City
Denver
State/Province
Colorado
ZIP/Postal Code
80206
Country
United States
City
Waterbury
State/Province
Connecticut
ZIP/Postal Code
06708
Country
United States
City
Cooper City
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
City
Kissimmee
State/Province
Florida
ZIP/Postal Code
34741
Country
United States
City
New Port Richey
State/Province
Florida
ZIP/Postal Code
34653
Country
United States
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32789
Country
United States
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31904
Country
United States
City
Duluth
State/Province
Georgia
ZIP/Postal Code
30096
Country
United States
City
Normal
State/Province
Illinois
ZIP/Postal Code
61761
Country
United States
City
Oak Lawn
State/Province
Illinois
ZIP/Postal Code
60453
Country
United States
City
River Forest
State/Province
Illinois
ZIP/Postal Code
60305
Country
United States
City
Avon
State/Province
Indiana
ZIP/Postal Code
46123
Country
United States
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40223
Country
United States
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55402
Country
United States
City
Plymouth
State/Province
Minnesota
ZIP/Postal Code
55441
Country
United States
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
City
Papillion
State/Province
Nebraska
ZIP/Postal Code
68046
Country
United States
City
Ocean
State/Province
New Jersey
ZIP/Postal Code
07712
Country
United States
City
Bronx
State/Province
New York
ZIP/Postal Code
10459
Country
United States
City
Rochester
State/Province
New York
ZIP/Postal Code
14618
Country
United States
City
Hendersonville
State/Province
North Carolina
ZIP/Postal Code
28739
Country
United States
City
High Point
State/Province
North Carolina
ZIP/Postal Code
27262
Country
United States
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73120
Country
United States
City
Medford
State/Province
Oregon
ZIP/Postal Code
97504
Country
United States
City
Portland
State/Province
Oregon
ZIP/Postal Code
97202
Country
United States
City
Greer
State/Province
South Carolina
ZIP/Postal Code
29651
Country
United States
City
Boerne
State/Province
Texas
ZIP/Postal Code
78006
Country
United States
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
City
Houston
State/Province
Texas
ZIP/Postal Code
77034
Country
United States
City
Humble
State/Province
Texas
ZIP/Postal Code
77338
Country
United States
City
McKinney
State/Province
Texas
ZIP/Postal Code
75069
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78207
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78249
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78251
Country
United States
City
Tomball
State/Province
Texas
ZIP/Postal Code
77375
Country
United States
City
Waco
State/Province
Texas
ZIP/Postal Code
76712
Country
United States
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22030
Country
United States
City
Henrico
State/Province
Virginia
ZIP/Postal Code
23233
Country
United States
City
Greenfield
State/Province
Wisconsin
ZIP/Postal Code
53228
Country
United States
City
Rio de Janeiro
State/Province
RJ
ZIP/Postal Code
22271-100
Country
Brazil
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90020-090
Country
Brazil
City
Florianopolis
State/Province
SC
ZIP/Postal Code
88040-970
Country
Brazil
City
Santo Andre
State/Province
SP
ZIP/Postal Code
09060-650
Country
Brazil
City
Santo Andre
State/Province
SP
ZIP/Postal Code
09080-000
Country
Brazil
City
Gabrovo
ZIP/Postal Code
5300
Country
Bulgaria
City
Razgrad
ZIP/Postal Code
7200
Country
Bulgaria
City
Ruse
ZIP/Postal Code
7002
Country
Bulgaria
City
Sofia
ZIP/Postal Code
1000
Country
Bulgaria
City
Sofia
ZIP/Postal Code
1431
Country
Bulgaria
City
Varna
ZIP/Postal Code
9019
Country
Bulgaria
City
Veliko Tarnovo
ZIP/Postal Code
5000
Country
Bulgaria
City
Brampton
State/Province
Ontario
ZIP/Postal Code
L6T 0G1
Country
Canada
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M9V 4B4
Country
Canada
City
Jablonec nad Nisou
ZIP/Postal Code
46601
Country
Czech Republic
City
Jindrichuv Hradec
ZIP/Postal Code
37701
Country
Czech Republic
City
Karlovy Vary - Stará Role
ZIP/Postal Code
360 17
Country
Czech Republic
City
Strakonice
ZIP/Postal Code
38601
Country
Czech Republic
City
Tbilisi
ZIP/Postal Code
0119
Country
Georgia
City
Auckland City
ZIP/Postal Code
0626
Country
New Zealand
City
Auckland
ZIP/Postal Code
1010
Country
New Zealand
City
Beckenham
ZIP/Postal Code
8024
Country
New Zealand
City
Bialystok
ZIP/Postal Code
15-276
Country
Poland
City
Krakow
ZIP/Postal Code
31-023
Country
Poland
City
Krakow
ZIP/Postal Code
31-159
Country
Poland
City
Lodz
ZIP/Postal Code
90-153
Country
Poland
City
Lublin
ZIP/Postal Code
20-089
Country
Poland
City
Poznan
ZIP/Postal Code
60-693
Country
Poland
City
Poznan
ZIP/Postal Code
60-823
Country
Poland
City
Tarnow
ZIP/Postal Code
33-100
Country
Poland
City
Wroclaw
ZIP/Postal Code
53-201
Country
Poland
City
Wroclaw
ZIP/Postal Code
54-239
Country
Poland
City
Caguas
ZIP/Postal Code
00725
Country
Puerto Rico
City
San Juan
ZIP/Postal Code
00909-1711
Country
Puerto Rico
City
San Juan
ZIP/Postal Code
00918
Country
Puerto Rico
City
Bucuresti
ZIP/Postal Code
030303
Country
Romania
City
Cluj-Napoca
ZIP/Postal Code
400371
Country
Romania
City
Iasi
ZIP/Postal Code
700115
Country
Romania
City
Oradea
ZIP/Postal Code
410176
Country
Romania
City
Timisoara
ZIP/Postal Code
300310
Country
Romania
City
Ekaterinburg
ZIP/Postal Code
620109
Country
Russian Federation
City
Moscow
ZIP/Postal Code
119991
Country
Russian Federation
City
Ryazan
ZIP/Postal Code
390011
Country
Russian Federation
City
Saint Petersburg
ZIP/Postal Code
190068
Country
Russian Federation
City
Saint Petersburg
ZIP/Postal Code
194295
Country
Russian Federation
City
Saratov
ZIP/Postal Code
410053
Country
Russian Federation
City
St Petersburg
ZIP/Postal Code
193231
Country
Russian Federation
City
St Petersburg
ZIP/Postal Code
197089
Country
Russian Federation
City
St. Petersburg
ZIP/Postal Code
194354
Country
Russian Federation
City
St. Petersburg
ZIP/Postal Code
197089
Country
Russian Federation
City
St. Petersburg
ZIP/Postal Code
197706
Country
Russian Federation
City
Spisska Nova Ves
ZIP/Postal Code
052 01
Country
Slovakia
City
Cape Town
ZIP/Postal Code
7130
Country
South Africa
City
Cape Town
ZIP/Postal Code
7530
Country
South Africa
City
Cape Town
ZIP/Postal Code
7700
Country
South Africa
City
Johannesburg
ZIP/Postal Code
2113
Country
South Africa
City
Lyttleton
ZIP/Postal Code
0157
Country
South Africa
City
Parow
ZIP/Postal Code
7505
Country
South Africa
City
Pretoria Gauteng Province
ZIP/Postal Code
0087
Country
South Africa
City
Soweto
ZIP/Postal Code
1818
Country
South Africa
City
Manchester
ZIP/Postal Code
M23 9QZ
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
29413502
Citation
Korenblat P, Kerwin E, Leshchenko I, Yen K, Holweg CTJ, Anzures-Cabrera J, Martin C, Putnam WS, Governale L, Olsson J, Matthews JG. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids. Respir Med. 2018 Jan;134:143-149. doi: 10.1016/j.rmed.2017.12.006. Epub 2017 Dec 13.
Results Reference
derived
Learn more about this trial
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
We'll reach out to this number within 24 hrs